^
Association details:
| Biomarker: | HRD |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Excerpt:
Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated...for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.
Source:
Title:
A clinical trial that examines whether the treatment with the medication olaparib in combination with the chemotherapy carboplatin is more effective than treatment with a standard chemotherapy (anthracycline/ taxane-based) against a specific type of breast cancer (triple-negative) with a biologic characteristic (homologous recombination deficiency)
Excerpt:
...Positive HRD status (centrally assessed) in core-biopsy sample of the breast5. ...
Trial ID:
Source:
Title:
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
Excerpt:
...Assess the efficacy of olaparib in HER2-negative early Breast Cancer and HRD (BRCA 1/2 mutations and/or HRD positive). ...
Trial ID:
Less C2 evidence
Source:
Title:
4MO - Homologous recombination (HR) status of platinum responsive advanced triple negative breast cancers (aTNBC) treated with olaparib as maintenance therapy
Published date:
05/07/2023
Excerpt:
We analysed the HR status of an enriched cohort of platinum-responsive aTNBC on the DORA study....45 patients (pts) were enrolled to receive maintenance olaparib (O) +/- durvalumab (D). HRD testing using Pillar Biosciences oncoReveal™ HRD Panel was performed on archival tissue....The mPFS of pts with HRD vs. no HRD was 7.8 months (m) (3.9 - not estimable) vs. 2.1 m (1.9 - 3.4), p=0.002. The association between mPFS and HRD did not vary by maintenance therapy. The mPFS of O pts (HRD n=9 vs. no HRD n=10) is 7.8 vs 1.9 m HR 0.3; 0.11-0.8 and of O+D pts (HRD n=12 vs. no HRD n=9) is 7.4 vs 3.3 m HR 0.34; 0.12-1.0. 11 of the 21 pts with HRD were on maintenance therapy for >6 months vs. 3 of the 19 pts without HRD.
Trial ID:
Source:
Title:
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
Published date:
11/23/2020
Excerpt:
Olaparib yielded a high clinical response rate in treatment-naïve TNBCs revealing HR deficiency. Eighteen out of 32 patients obtained an objective response (OR) to olaparib (56.3%).
DOI:
10.1016/j.annonc.2020.11.009
Trial ID:
